Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Institut Pasteur patents


Recent patent applications related to Institut Pasteur. Institut Pasteur is listed as an Agent/Assignee. Note: Institut Pasteur may have other listings under different names/spellings. We're not affiliated with Institut Pasteur, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Institut Pasteur-related inventors


Tal effector means useful for partial or full deletion of dna tandem repeats

The application relates to means, which derive from tal effectors and talens. The structure of the means of the application is especially adapted for partial or full deletion of at least one dna tandem repeat, more particularly for partial or full deletion of at least one dna tandem repeat in a double-stranded dna, more particularly for partial or full deletion of at least one dna tandem repeat, which is contained in a double-stranded dna and, which forms a complex secondary structure, such as a hairpin, a triple helix or a tetraplex secondary structure. ... Institut Pasteur

Live attenuated heterologous vaccine for leptospira

The present invention provides compositions or vaccines that contain a recombinant or an attenuated leptospira interrogans that elicit an immune response in animals against leptospira infection, including compositions comprising said recombinant or attenuated l. Interrogans, methods of vaccination against leptospira, and kits for use with such methods and compositions.. ... Institut Pasteur

Methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza

The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza. In particular, the present invention relates to a method of treating a bacterial superinfection post-influenza in a subject in need thereof comprising administering the subject with a therapeutically effective amount of a flagellin polypeptide optionally in combination with at least one antibiotic.. ... Institut Pasteur

Monomeric and functional adenylate cyclase cyaa toxin

The present invention discloses a procedure to produce a monomeric and functional form of bordetella sp, especially b. Pertussis, cyaa toxin that can be stably maintained in this functional monodisperse state, even in the absence of any chaotropic agent.. ... Institut Pasteur

Monoclonal antibodies specific for serogroup x of n. meningitidis and uses thereof in diagnosis

The present invention is directed to monoclonal antibodies and antigen-binding portions thereof, specific for the capsular polysaccharides of neisseria meningitidis serogroup x (nmx), wherein said antibodies or portions thereof are characterized by the sequences of the 6 cdr of the variable regions of the heavy and light chains. These antibodies are suitable for in vitro detection of neisseria meningitidis serogroup x especially in a biological sample without purification of the capsular polysaccharides. ... Institut Pasteur

Transgenic immunodeficient mouse expressing human sirp-alpha

The present invention provides a transgenic mouse which comprises a deficiency for murine t lymphocytes, b lymphocytes and nk cells, a deficiency for murine mhc class i and mhc class ii molecules, and a functional xenogenic sirpα transgene. This mouse is useful for in vivo screening of various compounds, including immuno-therapeutic agents and vaccines. ... Institut Pasteur

System, method and device for identifying discriminant biological factors and for classifying proteomic profiles

. . A system, method, computer readable medium and device for identifying discriminant spectrum clusters including receiving known input data set comprising spectra generated from biological samples known to either have or not have a biological condition where each spectrum may be either known to have been generated from the biological samples known to have or a biological condition, or from the biological samples known not to have same. A software module may apply quality control filters to the input data set to exclude spectra that do not meet the quality control filters, generate a set of remaining spectra, cluster same into a set of spectrum clusters by applying clustering parameters, and identify a set of discriminant spectrum clusters by examining whether each spectrum cluster exclusively contains only spectra generated from samples known to have a biological condition or exclusively contains spectra from samples known not to have the biological condition.. ... Institut Pasteur

Methods and pharmaceutical composition for modulation polarization and activation of macrophages

The present invention relates to methods and pharmaceutical composition for modulation polarization and activation of macrophages. In particular, the present invention relates to methods for modulating macrophage m1/m2 polarization in a subject in need thereof comprising administering to the subject a therapeutically effective amount of p2y2 receptor agonists or antagonists.. ... Institut Pasteur

Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof

The invention relates to antibodies, and antigen binding fragments thereof that potently neutralize infection of both rabv and non-rabv lyssaviruses. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized b cells and cultured plasma cells that produce such antibodies and antibody fragments. ... Institut Pasteur

Nitroalkene trolox derivatives and methods of use thereof in the treatment and prevention of inflammation related conditions

The present invention is directed to a class of anti-inflammatory, antioxidant nitroalkene compounds used in biological or biochemical applications to reduce oxidative stress or damage. The nitroalkene compounds described herein further avoid disadvantageous metabolism currently present in this field.. ... Institut Pasteur

Prevention and/or treatment of hearing loss or impairment

The present invention relates to the use of gasdermin, in particular of gasdermin a, gasdermin b, gasdermin c, gasdermin d, dfna5 or dfnb59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin a, gasdermin b, gasdermin c, gasdermin d, dfna5 or dfnb59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. ... Institut Pasteur

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. ... Institut Pasteur

Rna virus attenuation by alteration of mutational robustness and sequence space

The application generally relates to the attenuation of a rna virus or of a clone thereof and involves the alteration of sequence space, more particularly the reduction, of mutational robustness of said rna virus or clone. The means of the application are more particularly dedicated to the attenuation of an infectious rna virus or clone, for the production of immunogenic composition or vaccine. ... Institut Pasteur

Adam12 inhibitors and their use against inflammation-induced fibrosis

The present invention relates to the field of fibrosis and inflammation and more particularly to the use of adam12 (a disintegrin and metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of adam12 as a marker for inflammation-induced fibrosis and to the ablation of adam12 expressing cells as therapeutic approach to interfere with the development of pro-fibrotic cells.. ... Institut Pasteur

12/21/17 / #20170362607

Use of non-subtype b gag proteins for lentiviral packaging

The invention encompasses a lentiviral packaging vector comprising a non-subtype b gag-pol sequence, particularly a subtype d gag-pol sequence. The invention further encompasses methods for making and using these vectors. ... Institut Pasteur

11/23/17 / #20170336412

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. ... Institut Pasteur

11/23/17 / #20170334975

Polyclonal antibodies specific for serogroup x of n. meningitidis and uses thereof in diagnosis

Polyclonal antibodies specific for serogroup x of n. Meningitidis and uses thereof in diagnosis. ... Institut Pasteur

10/12/17 / #20170292951

Use of leptospira fainei serovar hurstbridge bacteria for diagnosing leptospirosis

The present invention discloses an in vitro method for diagnosing a leptospira infection in a biological sample of a subject, comprising a step of contacting said sample with bacterial cells of a serovar of the leptospira fainei species, preferably bacterial cells of the leptospira fainei serovar hurstbridge, or an antigenic fraction of said bacterial cells. In a preferred embodiment, said leptospira infection is not due to bacteria belonging to the serovar of the leptospira fainei species used in the diagnostic method.. ... Institut Pasteur

10/05/17 / #20170283490

Nanobodies suitable for neuron regeneration therapy

The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. ... Institut Pasteur

09/28/17 / #20170276672

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. ... Institut Pasteur

07/20/17 / #20170204145

Anti-inflammatory properties of a surface protein of propionibacterium freudenreichii

Disclosed is a polypeptide including or consisting of the amino acid sequence seq id no:1, for use in the treatment or prevention of an inflammatory disease. It further encompasses a nucleic acid sequence encoding a polypeptide, a vector including a nucleic acid and a host cell including a nucleic acid sequence and/or a vector, for use in the treatment or prevention of an inflammatory disease. ... Institut Pasteur

07/06/17 / #20170189496

Use of phosphorylation pathway-related factor in regulating function of regulatory t cell

A method for the treatment and/or the prevention of a disease or a symptom related to dysfunction of regulatory t cell immunomodulation includes administering to a subject in need thereof compositions that regulate regulatory t cell immunomodulatory function, in which the compositions may be prepared by contacting starting materials with phosphorylation pathway-related factors, the agonists or the antagonists thereof. The phosphorylation pathway-related factors are selected from: proto-oncogene protein pim1 and the coding sequence thereof. ... Institut Pasteur

06/15/17 / #20170169161

Method, device, and computer program for assembling pieces of chromosomes from one or several organisms

A method of assembling a sequence representing pieces of at least one chromosome from a set of raw sub-sequences representing dna fragments of a library including dna fragments including chains of contiguous nucleotides and including dna fragments including combinations of at least two chains of contiguous nucleotides. After having obtained first values representing contact frequencies between dna regions, the first values being associated with second values representing distances between the corresponding dna regions, the method includes: updating a genome structure based on the first and second values and based on a theoretical model associating a contact probability between dna regions with a distance between the corresponding dna regions, the updated genome structure being representative of the real genome structure of the chromosome; and updating parameters of the theoretical model as a function of the updated genome structure.. ... Institut Pasteur

05/04/17 / #20170121349

Anti-infective compounds

The present invention relates to small molecule compounds having the general formula (i): wherein a is a moiety selected from the group consisting of formulae (a) to (k) and their use in the treatment of bacterial infections, in particular tuberculosis.. . ... Institut Pasteur

04/20/17 / #20170108442

Enzyme-independent photon emission

The invention relates to a new method for generating a luminescent signal, which is based on an enzyme-independent photon emission mechanism (eipe), whereby luminescent light is generated when a bioluminescent substrate interact with a physical surface in the absence of any catalytic enzyme. In particular embodiments, the method is used to stimulate light emission by fluorescent molecules. ... Institut Pasteur

04/20/17 / #20170106073

Recombinant mycobacterium bovis bcg expressing antigens of the mycobacterium marinum esx-1 secretion system

Recombinant strains of mycobacterium bovis bacille calmette-guerin (m. Bovis bcg) comprising a heterologous nucleic acid sequence of mycobacterium marinum (m. ... Institut Pasteur

03/30/17 / #20170088843

Mgmt-based method for obtaining high yeilds of recombinant protein expression

The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-dna-methyltransferase enzyme (mgmt, ec 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. ... Institut Pasteur

03/23/17 / #20170079253

Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications

The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted h2 class i gene, a disrupted h2 class ii gene, a functional hla class i transgene, and a functional hla class ii transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both h2 class i and class ii molecules, wherein the transgenic mouse comprises a functional hla class i transgene and a functional hla class ii transgene. ... Institut Pasteur

03/16/17 / #20170073706

Production of 1-propanol

This invention encompasses methods of making 1-propanol. In some embodiments the methods comprise providing a cultured bacterial biofilm; culturing the bacterial biofilm under conditions suitable for production of 1-propanol; and collecting 1-propanol produced by the biofilm culture. ... Institut Pasteur

02/16/17 / #20170044181

Compounds for treating viral infections

The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis c virus (hcv).. . ... Institut Pasteur

02/09/17 / #20170037434

Chromosomal modification involving the induction of double-stranded dna cleavage and homologous recombination at the cleavage site

Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal dna in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. ... Institut Pasteur

02/02/17 / #20170029794

Tal effector means useful for partial or full deletion of dna tandem repeats

The application relates to means, which derive from tal effectors and talens. The structure of the means of the application is especially adapted for partial or full deletion of at least one dna tandem repeat, more particularly for partial or full deletion of at least one dna tandem repeat in a double-stranded dna, more particularly for partial or full deletion of at least one dna tandem repeat, which is contained in a double-stranded dna and, which forms a complex secondary structure, such as a hairpin, a triple helix or a tetraplex secondary structure. ... Institut Pasteur

01/26/17 / #20170021015

Novel immunoadjuvant flagellin-based compounds and use thereof

The present invention relates to novel peptide compounds derived from flagellin originating from salmonelle enterica that exhibit an in vivo immune adjuvant activity.. . ... Institut Pasteur

01/26/17 / #20170021004

Leptospira immunoprotective proteins and methods of identification and use thereof

The present invention provides compositions and methods for eliciting heterologous protective immunity in animals against leptospira spp. The leptospira spp. ... Institut Pasteur








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Institut Pasteur in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Institut Pasteur with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###